Biocryst Pharmaceuticals (BCRX) Other Accumulated Expenses (2013 - 2021)

Biocryst Pharmaceuticals' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $3.7 million for Q4 2021.

• Quarterly Other Accumulated Expenses fell 24.85% year-over-year to $3.7 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $3.7 million (down 24.85% YoY) and the FY2021 annual result came in at $3.7 million, down 24.85% from the prior year.
• Other Accumulated Expenses was $3.7 million for Q4 2021 at Biocryst Pharmaceuticals, down from $4.9 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $4.9 million in Q4 2020 and bottomed at $1.8 million in Q4 2018.
• A 5-year average of $3.2 million and a median of $3.5 million in 2019 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2019 — Other Accumulated Expenses surged 86.54% — and 2021, when it slipped 24.85%.
• Biocryst Pharmaceuticals' Other Accumulated Expenses stood at $2.2 million in 2017, then decreased by 17.19% to $1.8 million in 2018, then jumped by 86.54% to $3.5 million in 2019, then surged by 41.81% to $4.9 million in 2020, then declined by 24.85% to $3.7 million in 2021.
• Business Quant data shows BCRX's Other Accumulated Expenses at $3.7 million in Q4 2021, $4.9 million in Q4 2020, and $3.5 million in Q4 2019.